Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructs.
DNA plasmids and recombinant adenovirus serotype-5 (rAd5) vectors are being studied in human clinical trials as HIV-1 vaccine candidates. Each elicits robust T-cell responses and modest antibody levels. Since protein immunization alone elicits antibody but not CD8 T-cell responses, we studied protein boosting of DNA and rAd5 HIV-1 vaccine vectors. A single Env protein immunization provided a marked boost in antibody titer in guinea pigs primed with either DNA or rAd5 vaccines, and the resulting antibody binding and neutralization levels were similar to those attained after thee sequential protein immunizations. Since both T-cell immunity and neutralizing antibodies are thought to be required for protection against HIV-1, it may be possible to establish a balanced T-cell and antibody response with appropriate vectored vaccines and improve the neutralizing antibody titer with protein boosting.
Shu
Yuuei
Y
Vaccine Research Center, National Institutes of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
Winfrey
Sarah
S
Yang
Zhi-Yong
ZY
Xu
Ling
L
Rao
Srinivas S
SS
Srivastava
Indresh
I
Barnett
Susan W
SW
Nabel
Gary J
GJ
Mascola
John R
JR
D016915:AIDS Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D000256:Adenoviridae / Q000235:genetics / Q000276:immunology*; D000818:Animals; D000917:Antibody Formation / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D005260:Female; D015686:Gene Products, env / Q000235:genetics / Q000276:immunology; D006168:Guinea Pigs; D015497:HIV-1 / Q000235:genetics / Q000276:immunology*; D007117:Immunization, Secondary / Q000379:methods*; D010957:Plasmids / Q000235:genetics / Q000276:immunology; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*
D016915:AIDS Vaccines; D015686:Gene Products, env; D019444:Vaccines, DNA